Abstract:157 Background: 177Lu-PSMA (Lu-177) is an FDA-approved radiopharmaceutical agent for metastatic castration-resistant prostate cancer (mCRPC) progressed on prior chemotherapy and androgen receptor pathway inhibitor. The chronology, frequency and association PSA flare with Lu-177 on overall treatment outcome is unclear. Our retrospective study evaluates the association of PSA flare with clinical outcomes in mCRPC patients undergoing Lu-177 therapy. Methods: A retrospective study was conducted from 4/2022-8/2023 for patients treated with Lu-177 at the University of Kansas Cancer Center. PSA flare was defined as an initial rise in PSA levels that subsequently declined. A bone flare is defined as increased radiotracer uptake in bone scans. The primary outcome was progression-free survival (PFS). The secondary outcomes included overall survival (OS), PSA response, disease control rate (DCR) and safety. Results: A total of 46 patients were included in this study. The median age was 73 years (range: 52-100). Of these, 14 patients (30.4%) had completed 6 cycles of treatment. The median number Lu-177 cycles received was 3 (range: 1-6). PSA flare was observed in 7 patients (15.2%), and all of the PSA flare occurred in the first cycle. The median time from the start of treatment to the onset of PSA flare was 2 weeks (range: 1-4). The median change in PSA from baseline to flare increased by 41% (range: 22-1133%). The median time from PSA flare to PSA nadir was 12 weeks (range: 9-30). The median change in PSA from flare to nadir decreased by 73% (range: 57-95%). Bone flare was seen in 4 patients (13.8%) and the median onset time is 12 weeks (range: 10-17). There was no significant difference in PFS and OS between patients with or without PSA flare [median PFS: 7.1 vs. not reached (NR), p=0.11; median OS: NR vs. NR, p=0.27). A total of 22 patients (56.4%) exhibited a 50% PSA decrease (PSA 50). The proportion of patients with PSA 50 response was similar in both the PSA flare group (57.1%) and the non-PSA flare group (56.3%) (p=0.97). Among the patients who underwent radiographic assessment (n=29), the DCR was achieved in 66.7% vs. 60.9% of patients with or without PSA flare (p=0.79). The most common side effects in patients with or without flare included fatigue (71.4% vs. 66.7%, p=0.81), arthralgia (0% vs. 26.7, p=0.31), nausea (14.3% vs. 20%, p=0.73), diarrhea (28.6% vs. 10%, p=0.20), and anorexia (28.6% vs. 10%, p=0.20). Conclusions: PSA flare in patients treated with Lu-177 is not uncommon. Our study suggests the clinical response appears consistent regardless of the flare. Further studies and additional long-term follow-up are needed to validate our findings.

Clinical impact of C-reactive protein flare response in patients with advanced urothelial carcinoma who received pembrolizumab.

Clinical significance of early kinetics of C‐reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomes

C‐reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: An updated multicenter real-world experience applying different CRP kinetics definitions.

C-reactive protein (CRP) as a prognostic biomarker in patients with bladder cancer: A meta-analysis.

High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab

Early C-reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma

Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC).

Clinical efficacy of enfortumab-pembrolizumab combination therapy in locally advanced/metastatic urothelial carcinoma (UC): A real-world experience.

Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).

Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project

Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.

Development and validation of longitudinal c-reactive protein as dynamic response predictor for PD-L1 blockade in advanced NSCLC: Findings from four atezolizumab clinical trials.

A study of blood myeloid-derived suppressor cells for predicting pembrolizumab efficacy in patients with metastatic urothelial carcinoma.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177 Lu-PSMA treatment.

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial